

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 693 278 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

24.01.1996 Bulletin 1996/04

(51) Int. Cl.⁶: **A61K 7/06, A61K 7/48**

(21) Application number: **95110908.1**

(22) Date of filing: **12.07.1995**

(84) Designated Contracting States:

**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE**

(30) Priority: **19.07.1994 IT MI941497**

(71) Applicant: **INDENA S.p.A.**

I-20141 Milano (IT)

(72) Inventors:

- **Bombardelli, Ezio**
I-20141 Milano (IT)
- **Cristoni, Aldo**
I-20141 Milano (IT)
- **Morazzoni, Paolo**
I-20141 Milano (IT)

(74) Representative: **Bianchetti, Giuseppe**

I-20122 Milan (IT)

(54) **Combinations of vasoactive substances with fatty acids to prevent hair loss**

(57) The present invention relates to novel formulations useful in the preventive and curative treatment of hair loss and of seborrhea, containing coumarins such as khellin, visnadin, esculoside or alkaloids such as rau-basine, vincamine and derivatives thereof, combined with unsaturated and saturated fatty acids.

EP 0 693 278 A2

Description

The present invention relates to novel formulations useful in the preventive and curative treatment of hair loss, containing combinations of substances activating the microcirculation of "galea capitis" and products having antiseborrhoic and antiandrogen actions. It has surprisingly been found that formulations containing coumarins such as khellin, visnadin, esculoside, or alkaloids such as raubasine, vincamine and derivatives thereof, combined with unsaturated fatty acids such as ximenynic acid, the ethyl ester or other esters thereof, as well as acids such as lauric, myristic or isomyristic acids, are synergistically active in stimulating hair regrowth or in preventing its loss.

The vasokinetic activity of some of these substances, such as visnadin and khellin, had already been described in Patent application IT-21786A/89, which evidenced the effect thereof on the increase in the volume and in the blood flow rate at the level of the capillary network, and the use of these substances in peripheral vasculopathies and in primitive and secondary alopecias had been provided. Similarly, ximenynic acid free or in the form of triglyceride and generally of esters, was found to increase the blood flow with mechanisms different from those of visnadin and khellin (Patent IT-1223290).

Ximenynic acid and the esters thereof, when applied topically for a long time, exert a double effect at the cutaneous level: a microvasculokinetic one and antiseborrhoic one. Such two actions combined in the same molecule are particularly useful for keeping the skin effectively vascularized and at the same time dry thanks to a decreased sebum secretion. C₁₂ and C₁₄ acids, such as lauric, myristic and isomyristic acids, turned out to be strong inhibitors of dihydrotestosterone receptor binding, therefore, when suitably carried through the epicutaneous layer, they can exert a remarkable antiandrogen action thus contributing to a sebaceous regulation.

The combination of substances with vasokinetic activity (coumarins or alkaloids) with unsaturated fatty acids or the esters thereof as antiseborrhoic agents and with C₁₂ and C₁₄ acids with antiandrogen activity is one of the objects of the invention, and is proved to be particularly useful for stimulating the hair follicle and keeping the skin nourished thanks to a higher supply of blood and therefore of trophic substances; as result, after some days of treatment, a marked change in the skin occurs, with an increased number of perfused capillaries and absence of dandruff; hair follicles are normal and patent, and the sebum production is normal.

The above mentioned products, when combined together, are suitable for the administration in the form of hydroalcoholic lotions (which are those preferred for treatments of the scalp) or in the form of gels.

The preferred combinations for said treatments contain a combination of visnadin or khellin, in concentrations ranging from 0.2% to 3%; ximenynic acid or esters thereof, in concentrations ranging from 0.2% to 10% (preferably 1.5%); and lauric acid in concentrations ranging from 0.1% to 1% (preferably 0.5%). Visnadin and khellin can advantageously be replaced by esculoside or by its aglucon esculetin, in concentrations varying from 0.3% to 4% (preferably 2%).

Esculoside, in combination with ximenynic acid and the esters thereof and lauric, myristic and isomyristic acids, is particularly suitable for the treatment of early hair loss and for the stimulation of hair growth. The treatment with these substances can vary from a few days to 6 months.

PHARMACOLOGICAL EXPERIMENTATION

30 Subjects with primary or secondary alopecia were subdivided into 3 groups of 10 individuals each and treated for 90 days respectively with:

Group 1: a formulation containing 1% esculoside;

Group 2: a formulation containing 0.5% ximenynic acid and 0.2% lauric acid;

Group 3: a formulation containing 1% esculoside, 0.5% ximenynic acid and 0.2% lauric acid.

The vasokinetic effects and those on trichogram were evaluated both at the beginning and the end of the treatment.

Trichogram (basal and after 90 days) consists in withdrawing a suitable number (about 50) of hair by means of rubberized tweezers, both at the frontal-superior and latero-nuchal areas (Bosse K., Hautzart, 18, 35, 1967; Bosse K., Hautzart 18, 218, 1967).

Microscope observation of hair roots allows to evaluate the percentage of hair in anagen (growth), catagen (mature) or telogen (latency) phases. A telogen percentage higher than 10-15% (which is considered normal) gives a clinical evidence of a pathological condition of hair loss (Mortimer C.H., Rushton H., James K.C., Clin. Exp. Dermatol., 9, 342, 1984).

The vasokinetic effects were tested using the laser-Doppler flowmetry (Nilsson G.E., Tenland T., Oberg P.A., IEEE Transaction Biochem. Eng., 27, 12, 1980) using the PeriFlux^R PF3 flowmeter. This technique made it possible to measure the blood flow of the scalp of the subjects under test, under basal conditions and after administration of the test formulations, 15 minutes after the first administration (acute effect) and 8 hours after the administration, at the 30th, 60th and 90th day of treatment.

The results reported in Table 1 show the efficacy of esculoside as a vasokinetic agent.

The combination of said compound with ximenynic and lauric acids exerts a significant action on the hair follicle, so as to synergistically stimulate the regrowth or decrease the hair loss (13% telogen after a 90 day treatment), compared with the administration of the single components (Table 2).

Table 1
Effects on the average capillary blood flow induced by the topical administration of esculoside (group 1), ximenynic acid + lauric acid (group 2) and esculoside + ximenynic acid + lauric acid (group 3).

| Treatment | Capillary flow (AU \pm s.e.) | | | | |
|-----------|--------------------------------|-----------------|----------------|-----------------|-----------------|
| | Basal | 15 minutes | 30 days | 60 days | 90 days |
| Group 1 | 9.2 \pm 1.0 | 23.1 \pm 3.0* | 11.7 \pm 2.4 | 16.8 \pm 1.2* | 16.7 \pm 1.1* |
| Group 2 | 9.4 \pm 1.2 | 10.0 \pm 1.3 | 10.7 \pm 1.5 | 11.0 \pm 1.1 | 11.5 \pm 0.9 |
| Group 3 | 9.3 \pm 1.1 | 24.0 \pm 3.1* | 12.1 \pm 2.5 | 17.1 \pm 1.3* | 16.4 \pm 1.0* |

* = p < 0.01 vs. basal in the variance analysis of a split-plot design (Bonferroni t test)
N = 10

Table 2

Effects on trichogram induced by the topical administration (90 days) of esculoside (group 1), ximenynic acid + lauric acid (group 2) and esculoside + ximenynic acid + lauric acid (group 3).

| Treatment | Trichogram (% - m ± s.e.) | | |
|-----------|---------------------------|----------|---------|
| | anagen + catagen | telo-gen | |
| Group 1 | Before | 76 ± 3 | 24 ± 1 |
| | After 90 days | 79 ± 3 | 21 ± 1 |
| Group 2 | Before | 78 ± 2 | 22 ± 1 |
| | After 90 days | 80 ± 2 | 20 ± 1 |
| Group 3 | Before | 75 ± 2 | 25 ± 1 |
| | After 90 days | 87 ± 3* | 13 ± 1* |

* = p < 0.01 vs. basal based on the calculation of the Student t for paired data.

N = 10.

Examples of formulations useful for the treatment of scalp will be shown in the following non-limiting examples.

EP 0 693 278 A2

Example I - Lotion containing esculoside, ximenynic acid and lauric acid.

100 g of lotion contain:

| | |
|---------------------|----------------|
| Esculoside | 0.30 g |
| Ximenynic acid | 0.50 g |
| Lauric acid | 0.20 g |
| Butylhydroxytoluene | 0.10 g |
| Ethyl alcohol 50° | q.s. to 100 ml |

Example II - Lotion containing visnadin, ximenynic acid ethyl ester and lauric acid.

| | |
|--|----------------|
| Visnadin | 1.00 g |
| Ximenynic acid ethyl ester | 10.00 g |
| Lauric acid | 1.00 g |
| 80/20 Tetrameric cyclosiloxane and pentameric cyclosiloxane mixture (SF 1204 - GE silicones) | 15.00 g |
| Ethanol 95° | q.s. to 100 ml |

Claims

1. Cosmetic formulations containing

- a) one or more coumarins selected from khellin, visnadin, esculoside, esculetin, in combination with
- b) one or more alkaloids selected from raubasine, vincamine, derivatives thereof, and/or with
- c) one or more fatty acids and/or esters thereof, selected from ximenynic acid, saturated C₁₂-C₁₄ acids.

2. Formulations according to claim 1 for the preventive and curative treatment of hair loss and seborrhea.

3. Formulations according to claims 1 and 2, in the form of lotions.

4. Formulations according to claims 1-3, containing esculoside, ximenynic acid and lauric acid.

5. Formulations according to claims 1-3, containing visnadin, ximenynic acid ethyl ester and lauric acid.

6. The use of coumarins selected from khellin, visnadin, esculoside, esculetin and mixtures thereof, in combination with alkaloids selected from raubasine, vincamine, derivatives thereof and mixtures thereof and/or with fatty acids (and/or esters thereof) selected from ximenynic acid, saturated C₁₂-C₁₄ acids and mixtures thereof, for the preparation of cosmetic formulations.

PUB-NO: EP000693278A2
DOCUMENT-IDENTIFIER: EP 693278 A2
TITLE: Combinations of vasoactive
substances with fatty acids
to prevent hair loss
PUBN-DATE: January 24, 1996

INVENTOR-INFORMATION:

| NAME | COUNTRY |
|-------------------|----------------|
| BOMBARDELLI, EZIO | IT |
| CRISTONI, ALDO | IT |
| MORAZZONI, PAOLO | IT |

ASSIGNEE-INFORMATION:

| NAME | COUNTRY |
|-------------|----------------|
| INDENA SPA | IT |

APPL-NO: EP95110908
APPL-DATE: July 12, 1995

PRIORITY-DATA: IT00MI941497A (July 19, 1994)

INT-CL (IPC): A61K007/06 , A61K007/48

EUR-CL (EPC): A61K008/36 , A61K008/49 ,
A61K008/49 , A61K008/60 ,
A61Q005/00 , A61Q007/00

ABSTRACT:

CHG DATE=19990617 STATUS=O> The present invention relates to novel formulations useful in the preventive and curative treatment of hair loss and of seborrhea, containing coumarins such as khellin, visnadin, esculoside or alkaloids such as raubasine, vincamine and derivatives thereof, combined with unsaturated and saturated fatty acids.